Viscoelastometric Testing to Assess ...
Document type :
Compte-rendu et recension critique d'ouvrage
DOI :
PMID :
Title :
Viscoelastometric Testing to Assess Hemostasis of COVID-19: A Systematic Review
Author(s) :
Bareille, Marion [Auteur]
Université Catholique de Louvain = Catholic University of Louvain [UCL]
CHU UCL Namur
Hardy, Michaël [Auteur]
Université Catholique de Louvain = Catholic University of Louvain [UCL]
CHU UCL Namur
Douxfils, Jonathan [Auteur]
Université de Namur [Namur] [UNamur]
Roullet, Stéphanie [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
Lasne, Dominique [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Levy, Jerrold [Auteur]
Duke University [Durham]
Stépanian, Alain [Auteur]
Institut de Recherche Saint-Louis - Hématologie Immunologie Oncologie (Département de recherche de l’UFR de médecine ; ex- Institut Universitaire Hématologie-IUH) [IRSL]
Susen, Sophie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Frère, Corinne [Auteur]
Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases [ICAN]
CHU Pitié-Salpêtrière [AP-HP]
Lecompte, Thomas [Auteur]
Université de Genève = University of Geneva [UNIGE]
Mullier, François [Auteur]
CHU UCL Namur
Université Catholique de Louvain = Catholic University of Louvain [UCL]
Université Catholique de Louvain = Catholic University of Louvain [UCL]
CHU UCL Namur
Hardy, Michaël [Auteur]
Université Catholique de Louvain = Catholic University of Louvain [UCL]
CHU UCL Namur
Douxfils, Jonathan [Auteur]
Université de Namur [Namur] [UNamur]
Roullet, Stéphanie [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
Lasne, Dominique [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Levy, Jerrold [Auteur]
Duke University [Durham]
Stépanian, Alain [Auteur]
Institut de Recherche Saint-Louis - Hématologie Immunologie Oncologie (Département de recherche de l’UFR de médecine ; ex- Institut Universitaire Hématologie-IUH) [IRSL]
Susen, Sophie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Frère, Corinne [Auteur]
Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases [ICAN]
CHU Pitié-Salpêtrière [AP-HP]
Lecompte, Thomas [Auteur]
Université de Genève = University of Geneva [UNIGE]
Mullier, François [Auteur]
CHU UCL Namur
Université Catholique de Louvain = Catholic University of Louvain [UCL]
Journal title :
Journal of clinical medicine
Pages :
1740
Publisher :
MDPI
Publication date :
2021-04
ISSN :
2077-0383
English keyword(s) :
COVID-19
ClotPro
Quantra
ROTEM
SARS-CoV-2
TEG
coronavirus disease 2019
severe acute respiratory syndrome coronavirus 2
sonorheometry
thromboelastography
thromboelastometry
viscoelastic test
ClotPro
Quantra
ROTEM
SARS-CoV-2
TEG
coronavirus disease 2019
severe acute respiratory syndrome coronavirus 2
sonorheometry
thromboelastography
thromboelastometry
viscoelastic test
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Infection by SARS-CoV-2 is associated with a high risk of thrombosis. The laboratory documentation of hypercoagulability and impaired fibrinolysis remains a challenge. Our aim was to assess the potential usefulness of ...
Show more >Infection by SARS-CoV-2 is associated with a high risk of thrombosis. The laboratory documentation of hypercoagulability and impaired fibrinolysis remains a challenge. Our aim was to assess the potential usefulness of viscoelastometric testing (VET) to predict thrombotic events in COVID-19 patients according to the literature. We also (i) analyzed the impact of anticoagulation and the methods used to neutralize heparin, (ii) analyzed whether maximal clot mechanical strength brings more information than Clauss fibrinogen, and (iii) critically scrutinized the diagnosis of hypofibrinolysis. We performed a systematic search in PubMed and Scopus databases until 31st December 2020. VET methods and parameters, and patients' features and outcomes were extracted. VET was performed for 1063 patients (893 intensive care unit (ICU) and 170 non-ICU, 44 studies). There was extensive heterogeneity concerning study design, VET device used (ROTEM, TEG, Quantra and ClotPro) and reagents (with non-systematic use of heparin neutralization), timing of assay, and definition of hypercoagulable state. Notably, only 4 out of 25 studies using ROTEM reported data with heparinase (HEPTEM). The common findings were increased clot mechanical strength mainly due to excessive fibrinogen component and impaired to absent fibrinolysis, more conspicuous in the presence of an added plasminogen activator. Only 4 studies out of the 16 that addressed the point found an association of VETs with thrombotic events. So-called functional fibrinogen assessed by VETs showed a variable correlation with Clauss fibrinogen. Abnormal VET pattern, often evidenced despite standard prophylactic anticoagulation, tended to normalize after increased dosing. VET studies reported heterogeneity, and small sample sizes do not support an association between the poorly defined prothrombotic phenotype of COVID-19 and thrombotic events.Show less >
Show more >Infection by SARS-CoV-2 is associated with a high risk of thrombosis. The laboratory documentation of hypercoagulability and impaired fibrinolysis remains a challenge. Our aim was to assess the potential usefulness of viscoelastometric testing (VET) to predict thrombotic events in COVID-19 patients according to the literature. We also (i) analyzed the impact of anticoagulation and the methods used to neutralize heparin, (ii) analyzed whether maximal clot mechanical strength brings more information than Clauss fibrinogen, and (iii) critically scrutinized the diagnosis of hypofibrinolysis. We performed a systematic search in PubMed and Scopus databases until 31st December 2020. VET methods and parameters, and patients' features and outcomes were extracted. VET was performed for 1063 patients (893 intensive care unit (ICU) and 170 non-ICU, 44 studies). There was extensive heterogeneity concerning study design, VET device used (ROTEM, TEG, Quantra and ClotPro) and reagents (with non-systematic use of heparin neutralization), timing of assay, and definition of hypercoagulable state. Notably, only 4 out of 25 studies using ROTEM reported data with heparinase (HEPTEM). The common findings were increased clot mechanical strength mainly due to excessive fibrinogen component and impaired to absent fibrinolysis, more conspicuous in the presence of an added plasminogen activator. Only 4 studies out of the 16 that addressed the point found an association of VETs with thrombotic events. So-called functional fibrinogen assessed by VETs showed a variable correlation with Clauss fibrinogen. Abnormal VET pattern, often evidenced despite standard prophylactic anticoagulation, tended to normalize after increased dosing. VET studies reported heterogeneity, and small sample sizes do not support an association between the poorly defined prothrombotic phenotype of COVID-19 and thrombotic events.Show less >
Language :
Anglais
Popular science :
Non
Source :
Files
- document
- Open access
- Access the document
- jcm-10-01740-v2.pdf
- Open access
- Access the document
- document
- Open access
- Access the document
- jcm-10-01740-v2.pdf
- Open access
- Access the document